Literature DB >> 29620290

Significance of Lysyl oxidase‑like 2 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma.

Go Ninomiya1, Suguru Yamada1, Masamichi Hayashi1, Shigeomi Takeda1, Masaya Suenaga1, Hideki Takami1, Mitsuro Kanda1, Naoki Iwata1, Yukiko Niwa1, Chie Tanaka1, Daisuke Kobayashi1, Tsutomu Fujii1, Goro Nakayama1, Hiroyuki Sugimoto1, Masahiko Koike1, Michitaka Fujiwara1, Yasuhiro Kodera1.   

Abstract

In the present study, we investigated the role of lysyl oxidase‑like 2 (LOXL2), the correlation between LOXL2 and epithelial to mesenchymal transition (EMT) and the effects of using β‑aminopropionitrile (BAPN) to inhibit LOXL2 with the aim of reducing tumor progression in hepatocellular carcinoma (HCC). The expression level of LOXL2 was evaluated in HCC and adjacent non‑cancerous tissues using quantitative reverse transcription polymerase chain reaction and clinicopathological analyses. The effects of BAPN on cell proliferation, migration and invasion were investigated in vitro. Additionally, LOXL2 expression was assessed in the culture supernatants of HCC cell lines. Our results revealed that LOXL2 expression was higher in HCC cell lines and tissues. There was a significant correlation between EMT status and LOXL2 levels (P=0.004). BAPN reduced migration and invasion in HCC cells. HCC patients with high levels of LOXL2 expression had relatively shorter disease‑free survival (P=0.009) and overall survival (P=0.035). The expression level of LOXL2 was similar between cell supernatants and HCC cell lines. A multivariate analysis demonstrated that portal vein invasion (P=0.015), venous invasion (P=0.026), serum AFP (α‑fetoprotein) levels (P=0.019) and LOXL2 expression (P=0.009) were independent prognostic factors. Our results indicated that a higher level of LOXL2 may contribute to tumor progression, indicating that LOXL2 has clinical value as a therapeutic target in HCC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29620290     DOI: 10.3892/or.2018.6349

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Mass Spectrometry-Based Disulfide Mapping of Lysyl Oxidase-like 2.

Authors:  Alex A Meier; Eden P Go; Hee-Jung Moon; Heather Desaire; Minae Mure
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

2.  Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB.

Authors:  Faranak Mahjour; Vrinda Dambal; Neha Shrestha; Varun Singh; Vikki Noonan; Alpdogan Kantarci; Philip C Trackman
Journal:  Oncogenesis       Date:  2019-05-13       Impact factor: 7.485

Review 3.  Roles of Lysyl Oxidase Family Members in the Tumor Microenvironment and Progression of Liver Cancer.

Authors:  Hung-Yu Lin; Chia-Jung Li; Ya-Ling Yang; Ying-Hsien Huang; Ya-Tze Hsiau; Pei-Yi Chu
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

4.  Diagnostic Value, Prognostic Value, and Immune Infiltration of LOX Family Members in Liver Cancer: Bioinformatic Analysis.

Authors:  Chenyu Sun; Shaodi Ma; Yue Chen; Na Hyun Kim; Sujatha Kailas; Yichen Wang; Wenchao Gu; Yisheng Chen; John Pocholo W Tuason; Chandur Bhan; Nikitha Manem; Yuting Huang; Ce Cheng; Zhen Zhou; Qin Zhou; Yanzhe Zhu
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

Review 5.  Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases.

Authors:  Lara Perryman; Steven G Gray
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

6.  The prognostic value of the lysyl oxidase family in ovarian cancer.

Authors:  Miaomiao Ye; Junhan Zhou; Ying Gao; Shuya Pan; Xueqiong Zhu
Journal:  J Clin Lab Anal       Date:  2020-10-15       Impact factor: 3.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.